Amedisys (NASDAQ:AMED) Research Coverage Started at began coverage on shares of Amedisys (NASDAQ:AMED – Free Report) in a research report released on Monday. The brokerage issued a buy rating on the health services provider’s stock. Several other equities analysts have also recently weighed in on AMED. TD Cowen increased their price target on Amedisys from $84.00 to $101.00 and gave […]

Leave a Reply

Your email address will not be published.

Previous post Natuzzi (NYSE:NTZ) Earns Hold Rating from Analysts at
Next post Israel demolishing Gaza’s economy – UN